Regional sympathetic denervation after myocardial infarction: a follow-up study using [123I]MIBG.
Previous studies in dogs have shown that experimental infarction produces myocardial sympathetic denervation not only in the infarcted area, but also in a region apical to the infarction. In these dogs MIBG myocardial scintigraphy detected denervation but returned to normal in a few months at which time reinnervation was shown to have occurred. Myocardial sympathetic denervation was studied with MIBG scintigraphy in ten patients after their first acute transmural myocardial infarction; scans were repeated at 4 months, one year and 30 months to follow the time course of possible reinnervation. Except during the first 48 hours following the infarction, no therapy except for antiaggregants was administered to the patients; during this follow-up period no cardiac events were seen. One week after infarction, comparison of MIBG images with perfusion scans revealed that the denervated area was larger than the infarcted area; no difference in MIBG uptake by the infarcted myocardium was found during the 30 months follow-up.
Podio
V
V
Chair of Nuclear Medicine, University of Turin, Italy.
Spinnler
M T
MT
Spandonari
T
T
Moretti
C
C
Castellano
G
G
Bessone
M
M
Brusca
A
A
D019797:3-Iodobenzylguanidine; D000328:Adult; D005500:Follow-Up Studies; D006321:Heart / Q000000981:diagnostic imaging / Q000294:innervation*; D006801:Humans; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics; D007462:Iodobenzenes / Q000493:pharmacokinetics; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology*; D009206:Myocardium / Q000378:metabolism; D009416:Nerve Regeneration; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D013300:Streptokinase / Q000627:therapeutic use; D013564:Sympathetic Nervous System / Q000000981:diagnostic imaging / Q000473:pathology*; D013794:Thallium Radioisotopes; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use
D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D010975:Platelet Aggregation Inhibitors; D019275:Radiopharmaceuticals; D013794:Thallium Radioisotopes; D019797:3-Iodobenzylguanidine; D013300:Streptokinase; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator